结直肠癌PD-1和PD-L1信号通路及免疫治疗研究现状与进展OACSTPCD
Research Status and Progress of PD-1 and PD-L1 Signaling Pathways in and Immunotherapy for Colorectal Cancer
结直肠癌在我国具有较高的发病率及死亡率.免疫治疗近年来在实体瘤中取得长足进步,给结直肠癌患者带来了希望.然而目前对免疫治疗响应的dMMR/MSI-H型结直肠癌仅占10％左右,近90％的pMMR/MSS型结直肠癌患者尚不能从免疫治疗中获益,导致免疫治疗在结直肠癌中面临"冷""热"两种不同状态.同时除dMMR/MSI-H外,结直肠癌尚缺乏有效的免疫治疗生物标志物识别适宜人群.因此,本综述总结了结直肠癌PD-1和PD-L1信号通路及免疫治疗的研究现状,并探讨了免疫治疗生物标志物等问题,旨在为结直肠癌免疫治疗提供文献参考.
Colorectal cancer has the high incidence and mortality in China.Great strides have been made in immunother-apy for solid tumors in recent years,giving hope to patients with colorectal cancer.However,the current DNA mismatch re-pair-deficient(dMMR)/microsatellite instability-high(MSI-H)colorectal cancer in response to immunotherapy accounts on-ly for about 10％,and DNA mismatch repair-proficient(pMMR)/microsatellite stable(MSS)colorectal cancer patients,which accounts for about 90％,cannot benefit from immunotherapy.As a result,immunotherapy for colorectal cancer cur-rently faces two states,'cold'and'hot'.Apart from dMMR/MSI-H,there is still a lack of effective biomarkers in colorec-tal cancer to identify suitable populations for immunotherapy.Therefore,in this review,we summarized the current research status of PD-1 and PD-L1 signaling pathways in and immunotherapy for colorectal cancer,and discussed issues such as im-munotherapy biomarkers,aiming to provide evidence for immunotherapy for colorectal cancer.
计阳;李兆田;黄雪颖;燕锦
610054 成都,电子科技大学医学院646000 四川泸州,西南医科大学临床医学院610041 成都,四川省肿瘤临床医学研究中心,四川省肿瘤医院·研究所,四川省癌症防治中心,电子科技大学附属肿瘤医院大肠外科
临床医学
结直肠癌免疫治疗PD-1PD-L1生物标志物
Colorectal cancerImmunotherapyPD-1PD-L1Biomarker
《肿瘤预防与治疗》 2024 (010)
918-924 / 7
四川省肿瘤医院优秀青年基金项目(编号:YB2024019) This study was supported by grants from Sichuan Cancer Hospital(No.YB2024019).
评论